NCT02929498View on ClinicalTrials.gov

Safety, Clinical Activity, Pharmacokinetics (PK) and Pharmacodynamics Study of GSK2879552, Alone or With Azacitidine, in Subjects With High Risk Myelodysplastic Syndromes (MDS)

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

July 31, 2017

Primary Completion Date

January 31, 2018

Study Completion Date

January 31, 2018

Conditions
Myelodysplastic SyndromeMyelodysplastic Syndromes
Interventions
DRUG

GSK2879552

GSK2879552 will be administered orally as continuous daily dosing.

DRUG

Azacitidine

Azacitidine will be administered at 75 mg/m2 from Day 1 to Day 7 of each 28 day cycle by intravenous (iv) infusion or subcutaneous (sc) injection.

Trial Locations (6)

19111

GSK Investigational Site, Philadelphia

27705

GSK Investigational Site, Durham

28033

GSK Investigational Site, Madrid

30912

GSK Investigational Site, Augusta

46026

GSK Investigational Site, Valencia

77030

GSK Investigational Site, Houston

Sponsors

Lead Sponsor

GlaxoSmithKline

Collaborators (1)

Parexel
All Listed Sponsors
collaborator

Parexel

INDUSTRY

lead

GlaxoSmithKline

INDUSTRY

NCT02929498 - Safety, Clinical Activity, Pharmacokinetics (PK) and Pharmacodynamics Study of GSK2879552, Alone or With Azacitidine, in Subjects With High Risk Myelodysplastic Syndromes (MDS) | Biotech Hunter | Biotech Hunter